Episode

How Drug Price Negotiation Is Reshaping Clinical Trial Pipelines

Podcast
A Health Podyssey
Published
Feb 24, 2026
Duration seconds
1232
Processing state
not_requested
Canonical source
https://share.transistor.fm/s/13d8613e
Audio
https://media.transistor.fm/13d8613e/567db246.mp3
JSON
/v1/public/podcasts/a-health-podyssey-1366621/episodes/how-drug-price-negotiation-is-reshaping-clinical-trial-pipelines
Markdown
/podcast/a-health-podyssey-1366621/how-drug-price-negotiation-is-reshaping-clinical-trial-pipelines.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/a-health-podyssey-1366621/episodes/how-drug-price-negotiation-is-reshaping-clinical-trial-pipelines/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/a-health-podyssey-1366621/how-drug-price-negotiation-is-reshaping-clinical-trial-pipelines.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Health Affairs ' Rob Lott interviews So-Yeon Kang of Georgetown University about her recent paper exploring trends in biopharmaceutical clinical trials after The Inflation Reduction Act of 2022 authorized Medicare to negotiate prices for selected drugs. Order the January 2026 issue of Health Affairs . Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support , we can continue to keep our digital publication Forefront and podcast for everyone.